President Donald Trump issued an executive order Monday calling for the measles, mumps and rubella vaccine to be administered as three separate shots instead of one combined injection. The directive immediately collided with the realities of pharmaceutical development, public health logistics, and market economics—raising serious questions about whether the policy can ever be implemented.
Trump claimed without evidence that the combined MMR vaccine could be "quite lethal," though decades of large-scale studies have established its safety record. Medical experts across the country rejected the claim as baseless. The core problem isn't just scientific disagreement. It's institutional and practical: the manufacturers who produce MMR vaccines see no business case for splitting the shot, the regulatory approval process would take years, and the logistics of multiple doctor visits could actually worsen vaccination rates among children.
The Manufacturing Reality
Merck and GSK, the two companies that manufacture the MMR vaccine, have little financial incentive to develop three separate shots. William Moss, a pediatrician and epidemiological professor at Johns Hopkins University, was blunt about the economics: "I don't see any world in which vaccine manufacturers have any interest in developing and going through the rigorous regulatory process, getting FDA approval, doing the trials for monovalent measles, mumps, and rubella vaccines. It would be a foolish investment to make." Andrew Racine, president of the American Academy of Pediatrics, estimated that developing standalone shots would take more than a decade.
Merck stated in a Wednesday statement that evidence shows combination shots improve childhood vaccination outcomes by increasing completion rates and compliance. Separating the vaccine would mean children need six different doses in their early years instead of two. That's the opposite of streamlining healthcare delivery.
The Logistical Problem
Neil Maniar, a public health professor at Northeastern University, identified the core tension: "They're not solving a problem here. They're creating a new one. Based on false scientific rationale and political ideology, they're changing something that works into something that we have no idea what it will do." Multiple doctor visits create barriers, particularly for working parents and residents of rural areas where healthcare access is already limited.
The timing compounds the issue. Children receive their first MMR dose at 12 to 15 months of age, with a second dose at 4 to 6 years. The vaccination schedule is designed around both immune system readiness and disease risk. Spreading out these shots increases the window during which a child remains unprotected against preventable diseases.
Rising Measles Cases and Declining Confidence
The U.S. has already logged its highest number of measles cases in decades this year. Roughly 9% of parents report either skipping or delaying the MMR vaccine for their children, according to a 2025 survey by health policy organization KFF and the Washington Post. Two healthy children died from measles in the U.S. last year.
Dr. Racine warned that Trump's rhetoric and the executive order itself could further erode public confidence in the vaccine's safety. "Why would we not give children a vaccine that is safe, that prevents death?" he asked. Moss echoed the concern: "Some experts fear that splitting the MMR shot and Trump's broader effort to change federal vaccine recommendations could confuse parents and cause more of them to hold off on immunizing their children."
The irony isn't lost on public health experts. Trump has argued that children receive too many shots. Yet splitting the MMR vaccine would increase the total number of injections required. Moss called it "just so counterintuitive and counterproductive."
The Wakefield Connection
Experts traced the idea to Andrew Wakefield, a British gastroenterologist who published a paper in 1998 claiming to show a connection between MMR vaccines and autism. That paper was retracted, and Wakefield was removed from the U.K.'s medical register. The claim has been thoroughly debunked, with decades of safety data supporting the vaccine's overall safety. The CDC has documented only a small risk of febrile seizures associated with fever following vaccination—but such seizures cause no long-term harm.
Maniar emphasized the practical stakes: "We should be doing everything possible to increase those rates rather than implementing policies that present additional barriers to vaccination." The question now is whether states will align with the new federal guidance and whether manufacturers will invest resources in a product unlikely to generate returns before Trump's term ends.
Why This Matters:
This executive order illustrates a fundamental tension in governance: when policy goals collide with market incentives and logistical reality, implementation becomes the hard part. Pharmaceutical manufacturers won't develop a product they see as economically irrational. The regulatory process can't be rushed without compromising safety standards. And splitting a vaccine that's already proven effective risks creating new barriers to immunization at precisely the moment measles cases are rising. The policy also raises questions about whether government directives can override both scientific evidence and business judgment. Even if the order stands, its real-world impact depends on manufacturers choosing to invest resources, the FDA approving new formulations, and states deciding to follow suit—none of which appears likely.